









Markets
/
Stocks
/
nasdaq-inmd
/

Inmode Ltd

INMD

15.170USD

+0.240+1.61%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

958.88MMarket Cap

5.37P/E TTM



Inmode Ltd

15.170

+0.240+1.61%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

62 / 207

Overall Ranking

191 / 4723

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

16.250

Target Price

+8.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

Fairly Valued

The company’s latest PE is 6.21, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.79M shares, decreasing 34.97% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 2.33M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 95.60M, representing a year-over-year increase of 10.59%, while its net profit experienced a year-over-year increase of 12.28%.

Score

Industry at a Glance

Previous score

9.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.72

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.64

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.66

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.80, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is 6.21, which is 2.68% below the recent high of 6.38 and 2.50% above the recent low of 6.06.

Score

Industry at a Glance

Previous score

2.60

Change

-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 62/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Inmode Ltd is 16.00, with a high of 21.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

6.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

16.250

Target Price

+8.84%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Inmode Ltd

INMD

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 15.60 and the support level at 14.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.008

Buy

RSI(14)

56.840

Neutral

STOCH(KDJ)(9,3,3)

57.878

Neutral

ATR(14)

0.431

High Vlolatility

CCI(14)

62.295

Neutral

Williams %R

26.049

Buy

TRIX(12,20)

0.193

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

14.950

Buy

MA10

15.044

Buy

MA20

14.865

Buy

MA50

14.515

Buy

MA100

14.449

Buy

MA200

16.009

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 83.52%, representing a quarter-over-quarter decrease of 5.42%. The largest institutional shareholder is James Simons, holding a total of 2.33M shares, representing 3.68% of shares outstanding, with 12.95% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Mizrahy (Moshe)

3.50M

+74.50%

Kreindel (Michael)

3.11M

BoomerangFX International SRL

2.97M

-38.37%

Renaissance Technologies LLC

Star Investors

2.31M

+1.78%

DOMA Perpetual Capital Management, LLC

2.24M

LSV Asset Management

2.01M

+17.22%

BlackRock Institutional Trust Company, N.A.

4.91M

-7.03%

Meitav Dash Investments Ltd.

1.33M

-0.67%

Boston Trust Walden Company

1.37M

-0.15%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 5.09, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 2.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.